Emerging therapeutic modalities are redefining the analytical landscape. This session will explore how bioanalytical strategies can evolve from exploratory innovation to regulatory-ready implementation across complex modalities, including nucleic acid-based therapeutics, gene editing technologies, immune-effector cell therapies, and advanced biologic constructs. Through cross-sector perspectives, the program will examine how diverse analytical platforms—such as ligand binding assays, high-resolution mass spectrometry, nucleic acid quantification technologies, cellular functional assays, and integrative analytics—can be strategically combined to support development decision-making. Emphasis will be placed on fit-for-purpose assay design, orthogonal validation strategies, comparability assessment, and lifecycle management considerations. Speakers will present case-based examples illustrating how integrated bioanalytical frameworks can inform exposure–response relationships, immunogenicity risk, and translational endpoints while maintaining regulatory alignment and data integrity. The session will conclude with a moderated discussion addressing practical implementation challenges and opportunities for cross-disciplinary collaboration in supporting novel therapeutic modalities.
Learning Objectives:
Upon completion, participant will be able to describe key bioanalytical challenges associated with emerging therapeutic modalities and explain how they differ from traditional small molecule and biologic strategies.
Upon completion, participant will be able to compare exploratory and regulatory-ready bioanalytical approaches and identify fit-for-purpose strategies across different development stages.
Upon completion, participant will be able to design an integrated, risk-informed bioanalytical framework incorporating orthogonal methods to support exposure–response, immunogenicity, and regulatory decision-making.
